Low methionine levels can affect the production of A-adenosylmethionine (SAMe), a major methyl donor for the central nervous system and an essential nutrient required for the production of neurotransmitters
Pain during activity decreases, and endurance during rehabilitation exercises increases
The medication is in phase III trials and is expected to be available in markets by the end of 2026 or 2027
Semaglutide + tirzepatide, or semaglutide + retatrutide
Each vial contains 5mg of TB-500 (Thymosin Beta-4 analogue) and 5mg of BPC-157 (Body Protection Compound-157), co-lyophilised into a single vial for research convenience
The name alone does not guarantee quality, legal status, sterility, dose accuracy, or safety